Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludarabine Phosphate in Unresectable Melanoma: NCT06204991 Clinical Landscape Report 2026
16 October 2026
NCT06204991 clinical landscape for Unresectable Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
68Ga-DOTA-BPP in Liver metastases: NCT06203119 Clinical Landscape Report 2026
16 October 2026
NCT06203119 clinical landscape for Liver metastases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
XZ-120 in Neoplasms: NCT06206915 Clinical Landscape Report 2026
16 October 2026
NCT06206915 clinical landscape for Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Golcadomide Hydrochloride in Recurrent Follicular Lymphoma: NCT06209619 Clinical Landscape Report 2026
16 October 2026
NCT06209619 clinical landscape for Recurrent Follicular Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AMT-253 ADC in Advanced Malignant Solid Neoplasm: NCT06209580 Clinical Landscape Report 2026
16 October 2026
NCT06209580 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Allogenic gamma delta T cell therapy (Beijing GD Initiative Cell Therapy Technology) in Uveal Melanoma: NCT06212388 Clinical Landscape Report 2026
16 October 2026
NCT06212388 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CLIC-2201 in High grade B-cell lymphoma: NCT06208735 Clinical Landscape Report 2026
16 October 2026
NCT06208735 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IPG-1094 in Locally Advanced Malignant Solid Neoplasm: NCT06212076 Clinical Landscape Report 2026
16 October 2026
NCT06212076 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
IMM-6-415 in Locally Advanced Malignant Solid Neoplasm: NCT06208124 Clinical Landscape Report 2026
16 October 2026
NCT06208124 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Tizetatug rezetecan in Triple Negative Breast Cancer: NCT06210438 Clinical Landscape Report 2026
16 October 2026
NCT06210438 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Renal Cell Carcinoma: NCT06211790 Clinical Landscape Report 2026
16 October 2026
NCT06211790 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Axitinib in Renal Cell Carcinoma: NCT06211114 Clinical Landscape Report 2026
16 October 2026
NCT06211114 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.